Pricing of oral generic cancer medicines in 25 European countries; findings and implications
| Autor: | Stuart McTaggart, Irene Langer, Ieva Greiciute-Kuprijanov, Patricia Vella Bonanno, Anne Marthe Ringerud, Angela Timoney, Jurij Fürst, John Yfantopoulos, Arianit Jakupi, Tatjana Ponorac, Robert Sauermann, Vanda Marković-Peković, Dzintars Gotham, D Tomek, Admir Malaj, Corinne Zara, Christian Hierländer, Peter Skiold, Vincent de Valk, Guenka Petrova, Antony P. Martin, JF (Hans) Piepenbrink, Jolanta Gulbinovič, Janet Wale, Iris Hoxha, Wouter Hamelinck, Maria Juhasz-Haverinen, Nataša Grubiša, Steven Simoens, Catherine Sermet, Ott Laius, Gisbert Selke, Robert Plisko, Celia C. Rothe, Tomasz Bochenek, Andrew F. Hill, Tanja Novakovic, Zornitza Mitkova, Ileana Mardare, Alan Haycox, Roberta Joppi, Carolin Hagen, Magdalene Wladysiuk, Amanj Kurdi, Elita Poplavska, Brian Godman, Merce Obach Cortadellas, Mark Parker |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
RM
Public economics business.industry Health authority Cancer Pharmacy medicine.disease 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Drug Guides Sustainability medicine Business health care economics and organizations 030217 neurology & neurosurgery Health policy Qualitative research |
| Zdroj: | Generics and Biosimilars Initiative Journal |
| ISSN: | 2033-6403 |
| Popis: | Introduction: There are appreciable concerns among European health authorities with growing expenditure on cancer medicines and issues of sustainability. The enhanced use of low cost generics could help. Aims: Consequently, there is a need to comprehensively document current and future arrangements regarding the pricing of generic cancer medicines across Europe, and whether these are indication specific, as well as how this translates into actual prices to provide future direction. Methodology: Mixed method approach with qualitative research among senior health authority personnel and their advisers. Quantitative research via health authority databases to ascertain current prices for oral cancer medicines that had lost their patent and the influence of population size and economics on prices. Results: 25 European countries participated. Currently we see (a) variable approaches to the pricing of generic cancer medicines, which will continue; (b) no concerns with substitution for oral generic cancer medicines; (c) substantial price reductions versus originators for generic capecitabine (up to -93.1%), generic imatinib (up to -97.8%) and generic temozolomide (up to -80.7%). Prices for oncology medicines are not indication specific, and are not affected by population size although influenced by pricing approaches. There have also been price increases for some non-patented cancer medicines following manufacturer changes although now stabilising. Conclusion: The considerable price reductions seen for some generics means health authorities should further encourage the use of generic oncology medicines when they become available to fund increased volumes and new valued cancer medicines. Countries are also starting to address price increases for generics following changes in the manufacturer |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|